Jean-Claude BJ - Search Results

1

Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class.

Qiu Q, Larroque AL, Gibbs B, Fang Y, Lakhrissi Y, Soucy JP, Mzengeza S, Rachid Z, Jean-Claude BJ. Qiu Q, et al. Drug Metab Lett. 2009 Jan;3(1):1-9. doi: 10.2174/187231209787176344. Drug Metab Lett. 2009. PMID: 19356110

2

Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.

Matheson SL, McNamee J, Jean-Claude BJ. Matheson SL, et al. J Pharmacol Exp Ther. 2001 Mar;296(3):832-40. J Pharmacol Exp Ther. 2001. PMID: 11181914

3

Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.

Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Brahimi F, et al. J Pharmacol Exp Ther. 2002 Oct;303(1):238-46. doi: 10.1124/jpet.102.039099. J Pharmacol Exp Ther. 2002. PMID: 12235257

4

The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.

Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, Jean-Claude BJ. Qiu Q, et al. Cancer Chemother Pharmacol. 2003 Jan;51(1):1-10. doi: 10.1007/s00280-002-0524-5. Epub 2002 Nov 1. Cancer Chemother Pharmacol. 2003. PMID: 12497200

5

Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.

Matheson SL, McNamee JP, Jean-Claude BJ. Matheson SL, et al. Cancer Chemother Pharmacol. 2003 Jan;51(1):11-20. doi: 10.1007/s00280-002-0525-4. Epub 2002 Nov 22. Cancer Chemother Pharmacol. 2003. PMID: 12497201

6

Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase.

Rachid Z, Katsoulas A, Brahimi F, Jean-Claude BJ. Rachid Z, et al. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3297-300. doi: 10.1016/s0960-894x(03)00553-5. Bioorg Med Chem Lett. 2003. PMID: 12951113

7

The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".

Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ. Rachid Z, et al. J Med Chem. 2003 Sep 25;46(20):4313-21. doi: 10.1021/jm030142e. J Med Chem. 2003. PMID: 13678409

8

Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.

Banerjee R, Rachid Z, McNamee J, Jean-Claude BJ. Banerjee R, et al. J Med Chem. 2003 Dec 4;46(25):5546-51. doi: 10.1021/jm030423m. J Med Chem. 2003. PMID: 14640561

9

Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line.

Qiu Q, Dudouit F, Banerjee R, McNamee JP, Jean-Claude BJ. Qiu Q, et al. Prostate. 2004 Apr 1;59(1):13-21. doi: 10.1002/pros.10353. Prostate. 2004. PMID: 14991862

10

The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.

Matheson SL, Brahimi F, Jean-Claude BJ. Matheson SL, et al. Biochem Pharmacol. 2004 Mar 15;67(6):1131-8. doi: 10.1016/j.bcp.2003.10.035. Biochem Pharmacol. 2004. PMID: 15006549

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters